Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment-dependent Hormone Receptor Expression in

Eleonora Y Khlebus1, Veena K Vuttaradhi1, Sammy Ferri-Borgogno1

  • 1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

PubMed

Insights

Researchers identified two distinct subtypes of adult-type granulosa cell tumors (AGCTs) based on their microenvironment. This discovery offers new avenues for personalized treatment strategies for this rare ovarian cancer.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Adult-type granulosa cell tumors (AGCTs) are rare ovarian cancers with limited treatment options for recurrent disease.
  • Understanding the tumor microenvironment is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the spatial features and cellular interactions within the AGCT tumor microenvironment.
  • To identify distinct subtypes of AGCT based on microenvironment composition.

Main Methods:

  • Imaging mass cytometry was used to analyze 130 regions from 24 AGCT samples, profiling over 900,000 single cells with a 34-marker panel.
  • Analysis focused on immune cell infiltration, extracellular matrix components, and specific cell populations like FOXL2+ cells.

Main Results:

  • AGCTs exhibit an immune "cold" phenotype, with increased macrophage abundance in recurrent tumors.
  • Two distinct AGCT subtypes (AGCT-1 and AGCT-2) were identified, characterized by differences in FOXL2+ cell distribution, progesterone receptor expression, and transcriptomic profiles.
  • Tumor heterogeneity was observed, including variable presence of FOXL2+ cells within collagen-rich areas.

Conclusions:

  • The study highlights the roles of macrophages, FOXL2+ subpopulations, and the extracellular matrix in AGCT progression.
  • The identified AGCT subtypes present distinct vulnerabilities, suggesting potential for subtype-specific, personalized therapeutic approaches for this rare malignancy.